The drug effects questionnaire: psychometric support across three drug types

被引:182
作者
Morean, Meghan E. [1 ]
de Wit, Harriet [2 ]
King, Andrea C. [2 ]
Sofuoglu, Mehmet [1 ]
Rueger, Sandra Y. [2 ,3 ]
O'Malley, Stephanie S. [1 ]
机构
[1] Yale Univ, Sch Med, Connecticut Mental Hlth Ctr, Dept Psychiat, New Haven, CT 06519 USA
[2] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL USA
[3] Wheaton Coll, Billy Graham Ctr, Dept Psychol, Wheaton, IL 60187 USA
关键词
Amphetamine; Alcohol; Nicotine; Drug; ABUSE LIABILITY; ALCOHOL; AMPHETAMINE; ALPRAZOLAM; NALTREXONE; INCREASES; RESPONSES; HEROIN; LIGHT; MOOD;
D O I
10.1007/s00213-012-2954-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The Drug Effects Questionnaire (DEQ) is widely used in studies of acute subjective response (SR) to a variety of substances, but the format of the DEQ varies widely across studies, and details of its psychometric properties are lacking. Thus, the field would benefit from demonstrating the reliability and validity of the DEQ for use across multiple substances. The current study evaluated the psychometric properties of several variations of DEQ items, which assessed the extent to which participants (1) feel any substance effect(s), (2) feel high, (3) like the effects, (4) dislike the effects, and (5) want more of the substance using 100-mm visual analog scales. DEQ data from three placebo-controlled studies were analyzed to examine SR to amphetamine, nicotine, and alcohol. We evaluated the internal structure of the DEQ for use with each substance as well as relationships between scale items, measures of similar constructs, and substance-related behaviors. Results provided preliminary psychometric support for items assessing each DEQ construct (feel, high, dislike, like, and more). Based on the study results, we identify several common limitations of extant variants of the DEQ and recommend an improved version of the measure. The simplicity and brevity of the DEQ combined with its promising psychometric properties support its use in future SR research across a variety of substances.
引用
收藏
页码:177 / 192
页数:16
相关论文
共 38 条
  • [1] On the adaptive control of the false discovery fate in multiple testing with independent statistics
    Benjamini, Y
    Hochberg, Y
    [J]. JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS, 2000, 25 (01) : 60 - 83
  • [2] Caffeine's influence on nicotine's effects in nonsmokers
    Blank, Melissa D.
    Kleykamp, Bethea A.
    Jennings, Janine M.
    Eissenberg, Thomas
    [J]. AMERICAN JOURNAL OF HEALTH BEHAVIOR, 2007, 31 (05) : 473 - 483
  • [3] SELF-ADMINISTRATION OF PENTOBARBITAL IN LIGHT AND MODERATE ALCOHOL DRINKERS
    COLEHARDING, S
    DEWIT, H
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1992, 43 (02) : 563 - 569
  • [4] Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals
    Comer, SD
    Sullivan, MA
    Walker, EA
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) : 1320 - 1330
  • [5] Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers
    Comer, SD
    Walker, EA
    Collins, ED
    [J]. PSYCHOPHARMACOLOGY, 2005, 181 (04) : 664 - 675
  • [6] Cox L S, 2001, Nicotine Tob Res, V3, P7, DOI 10.1080/14622200020032051
  • [7] Do initial responses to drugs predict future use or abuse?
    de Wit, Harriet
    Phillips, Tamara J.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2012, 36 (06) : 1565 - 1576
  • [8] OPRM1 gene variants modulate amphetamine-induced euphoria in humans
    Dlugos, A. M.
    Hamidovic, A.
    Hodgkinson, C.
    Shen, P. H.
    Goldman, D.
    Palmer, A. A.
    de Wit, H.
    [J]. GENES BRAIN AND BEHAVIOR, 2011, 10 (02) : 199 - 209
  • [9] Increased sensitivity to alprazolam in females with a paternal history of alcoholism
    Evans, SM
    Levin, FR
    Fischman, MW
    [J]. PSYCHOPHARMACOLOGY, 2000, 150 (02) : 150 - 162
  • [10] The effects of alprazolam and buspirone in light and moderate female social drinkers
    Evans, SM
    Levin, FR
    [J]. BEHAVIOURAL PHARMACOLOGY, 2002, 13 (5-6): : 427 - 439